secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001193125-23-174006
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics signs $200M ATM equity distribution agreement with Jefferies
--------------------------------------------------------------------------------

- New Sales Agreement with Jefferies allows issuance of up to $200M in common stock at 3.0% commission rate.
- Prior Cantor Fitzgerald ATM terminated; had raised $1.4M of its $75M capacity before termination.
- Proceeds to fund R&D for ELVN-001, ELVN-002, other preclinical programs, and general corporate purposes.
- Registration Statement (S-3) filed but not yet effective; no sales may occur until declared effective by SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523174006/0001193125-23-174006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523174006/d518523d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-174006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer